Showing results (1341-1350 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|March 4, 2009
Challenges in merging Medicaid and Medicare databases to obtain healthcare costs for dual-eligible beneficiaries: using diabetes as an exampleCecilia M Prela, Greg A Baumgardner, Gayle E Reiber, et al.Pharmacoeconomics|June 3, 2009
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX studyLaura T Pizzi, Amy Talati, Eric Gemmen, et al.Pharmacoeconomics|October 15, 2008
Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipientsGerardo Machnicki, Jean-Francois Ricci, Daniel C Brennan, et al.Pharmacoeconomics|September 13, 2005
The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccineRobert Welte, Caroline L Trotter, W John Edmunds, et al.Pharmacoeconomics|September 13, 2005
A systematic review of patient-reported outcome instruments measuring sleep dysfunction in adultsEmily Beth Devine, Zafar Hakim, Jesse GreenPharmacoeconomics|September 13, 2005
Cost-benefit analysis of vaccination against tick-borne encephalitis among French troopsGuillaume Desjeux, Laurent Galoisy-Guibal, Cyrille ColinPharmacoeconomics|July 13, 2004
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UKAndrew Moore, Ceri Phillips, Elke Hunsche, et al.Pharmacoeconomics|July 13, 2004
Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in FranceJean-Pierre Marissal, Bernard SelkePharmacoeconomics|August 6, 2004
Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthmaRichard D O'Connor, Harold Nelson, Rohit Borker, et al.Pharmacoeconomics|February 3, 2007
Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives?Jonathan D Ketcham, Andrew J EpsteinPageof 336